Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
Clinical trial NCT03491215 · COMPLETED
Trial details
- NCT number
- NCT03491215
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-21
- Primary completion
- 2021-03-11
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.